Toxicologic studies of a superpotent alpha-melanotropin, [Nle4, D-Phe7]alpha-MSH
- PMID: 2852652
- DOI: 10.1007/BF00173642
Toxicologic studies of a superpotent alpha-melanotropin, [Nle4, D-Phe7]alpha-MSH
Abstract
A toxicology study was performed in mice given a superpotent alpha melanocyte stimulating hormone (MSH) analog. This 13 amino acid derivative, [Nle4, D-Phe7]alpha-MSH or NDP-MSH, is a melanotropin which is very slowly biodegraded in vivo and is active at 1/1,000 the concentration of natural alpha-MSH. Mice were administered up to 2 mg/kg of the analog daily and weekly over 4 or 12 weeks by both topical application (in 90% DMSO) or by IP injections (in physiologic saline). At the end of this period, no toxic effects were observed in various organs, on hematologic indices, or on weight gain. A slight increase in triglyceride and platelet levels were noted in mice given the analog weekly for 12 weeks. There was no evidence of an effect on behavior nor ACTH-like endocrine actions such as elevated serum cortisol levels. Transdermal drug delivery studies performed in vitro showed reproducible diffusion of the NDP-MSH analog through full-thickness mouse skin. Approximately 0.002% to 0.05% of a 10(-4) M preparation was transdermally delivered using a DMSO/water solution or a PEG/alcohol cream base, respectively. This superpotent analog is now entering a Phase I clinical trial with possible therapeutic applications for the treatment of hypomelanotic disorders such as vitiligo and for pharmacologic tanning without the need for sunlight exposure.
Similar articles
-
[Nle4, D-Phe7]-alpha-MSH: a superpotent melanotropin that "irreversibly" activates melanoma tyrosinase.Endocr Res. 1985;11(3-4):157-70. doi: 10.1080/07435808509032974. Endocr Res. 1985. PMID: 3009169
-
Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors.J Med Chem. 1995 Sep 1;38(18):3454-61. doi: 10.1021/jm00018a005. J Med Chem. 1995. PMID: 7658432
-
Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics.J Med Chem. 1989 Dec;32(12):2555-61. doi: 10.1021/jm00132a010. J Med Chem. 1989. PMID: 2555512
-
[Alpha-melanocyte-stimulating hormone. From bench to bedside].Hautarzt. 2010 Jun;61(6):497-504. doi: 10.1007/s00105-009-1891-1. Hautarzt. 2010. PMID: 20512306 Review. German.
-
A review and update on melanocyte stimulating hormone therapy: afamelanotide.J Drugs Dermatol. 2013 Jul 1;12(7):775-9. J Drugs Dermatol. 2013. PMID: 23884489 Review.
Cited by
-
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.Clin Pharmacokinet. 2017 Aug;56(8):815-823. doi: 10.1007/s40262-016-0501-5. Clin Pharmacokinet. 2017. PMID: 28063031 Review.
-
Alpha-melanocyte stimulating hormone ameliorates disease activity in an induced murine lupus-like model.Clin Exp Immunol. 2014 Aug;177(2):381-90. doi: 10.1111/cei.12336. Clin Exp Immunol. 2014. PMID: 24666423 Free PMC article.
-
Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.Biochim Biophys Acta Mol Basis Dis. 2017 Oct;1863(10 Pt A):2414-2435. doi: 10.1016/j.bbadis.2017.03.020. Epub 2017 Mar 29. Biochim Biophys Acta Mol Basis Dis. 2017. PMID: 28363699 Free PMC article. Review.
-
Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole.Neuropsychopharmacology. 2015 Jul;40(8):1856-65. doi: 10.1038/npp.2015.35. Epub 2015 Feb 5. Neuropsychopharmacology. 2015. PMID: 25652247 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources